ASCENDIS PHARMA
Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugs of proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosin... g frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.
ASCENDIS PHARMA
Industry:
Biotechnology Clinical Trials Health Care
Founded:
2006-01-01
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.ascendispharma.com
Total Employee:
501+
Status:
Active
Contact:
650 352 8389
Email Addresses:
[email protected]
Total Funding:
1.43 B USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon WordPress Content Delivery Network Global Site Tag HSTS IPv6 Organization Schema
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Carebox Healthcare
Carebox connects patients and physicians exploring treatment options with clinical trials.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Press Ganey
Press Ganey offers an integrated suite of solutions that enable enterprise transformation across the patient journey.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
VBI Vaccines
VBI Vaccinea is a biopharmaceutical company developing novel technologies that seek to expand vaccine.
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2007-12-13 | Complex Biosystems | Complex Biosystems acquired by Ascendis Pharma | N/A |
Investors List
Royalty Pharma
Royalty Pharma investment in Post-IPO Debt - Ascendis Pharma
Sofinnova Investments
Sofinnova Investments investment in Post-IPO Equity - Ascendis Pharma
Venrock
Venrock investment in Series D - Ascendis Pharma
Sofinnova Investments
Sofinnova Investments investment in Series D - Ascendis Pharma
Rock Springs Capital
Rock Springs Capital investment in Series D - Ascendis Pharma
RA Capital Management
RA Capital Management investment in Series D - Ascendis Pharma
OrbiMed
OrbiMed investment in Series D - Ascendis Pharma
Vivo Capital
Vivo Capital investment in Series D - Ascendis Pharma
Gilde Healthcare
Gilde Healthcare investment in Series A - Ascendis Pharma
TechnoStart
TechnoStart investment in Series A - Ascendis Pharma
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2021-01-08 | Visen Pharmaceuticals | Ascendis Pharma investment in Series B - Visen Pharmaceuticals | 150 M USD |
2018-11-13 | Visen Pharmaceuticals | Ascendis Pharma investment in Series A - Visen Pharmaceuticals | 40 M USD |
Official Site Inspections
http://www.ascendispharma.com Semrush global rank: 1.79 M Semrush visits lastest month: 12.53 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ascendis Pharma"
About Us - Ascendis Pharma
Build integrated commercial organization in North America and select European countries; Establish global commercial presence through partners with local expertise and infrastructure in other geographic areas; ... You are about to …See details»
Careers - Ascendis Pharma
We are committed to working with and providing reasonable accommodations to job applicants with disabilities. If you have a disability that limits your ability to apply for a position through our …See details»
Ascendis Pharma: We’ve got making a difference for patients …
We apply our TransCon technology platform to build a leading, fully integrated biopharma company & make a meaningful difference for patients, caregivers & HCPs.See details»
Investors & News | Ascendis Pharma
Nov 7, 2024 Ascendis Pharma is applying our innovative TransConâ„¢ technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful …See details»
Ascendis Pharma - LinkedIn
Ascendis Pharma Biotechnology Research Hellerup, Capital Region of Denmark 60,342 followers Committed to making a meaningful difference for patientsSee details»
Pendopharm signs exclusive distribution agreement with Ascendis …
Montreal, July 9, 2024 – Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S (NASDAQ: ASND) …See details»
Ascendis Pharma Company Profile | Management and Employees …
SQL International Organization for Standardization . Other IT Infrastructure Software (5 Technologies) Open AI . Redwood Software Reference Solutions . IT Lab IT Lab . ...See details»
Ascendis Pharma - Crunchbase Company Profile
Organization. Ascendis Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Ascendis Pharma built a high-value pipeline that aims to change the clinical treatment …See details»
Sustainability & P|ESG Report 2023 - Ascendis Pharma
Multifaceted organization to support our ongoing commercialization and serve as foundation for future Endocrinology Rare Disease product launches. We are furthermore expanding our …See details»
Ascendis Pharma - Overview, News & Similar companies - ZoomInfo
Jul 26, 2024 www.ascendispharma.com. Revenue $352.6 Million. Stock Symbol ASND. Industry Pharmaceuticals Healthcare . Most Recent Scoops. Aug 14 2024. Hiring Plans. Jul 27 2024. …See details»
Leadership - Ascendis Pharma
Sherrie Glass was named Chief Business Officer at Ascendis Pharma in September 2024. Prior to joining Ascendis, Ms. Glass was Senior Vice President of Enterprise Strategy & Operational …See details»
Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual …
Jan 11, 2021 The company’s US commercial organization is in place and commercial manufacturing is ongoing for the potential launch of lonapegsomatropin in pediatric GHD …See details»
About Us - Ascendis Pharma US
Build integrated commercial organization in North America and select European countries; ... You are about to access www.ascendispharma.com. Click below if you wish to proceed. GO …See details»
Corporate Responsibility - Ascendis Pharma
OUR APPROACH to CORPORATE RESPONSIBILITY. As a company committed to making a difference in the lives of patients, responsible corporate governance supports our business …See details»
Ascendis Pharma A/S Announces Planned Board Transition
“With the company transitioning from a developmental stage company to a global commercial organization, I want to focus my efforts on serving my role as the Company’s Chief Legal …See details»
Ascendis Pharma - Overview, News & Similar companies - ZoomInfo
Www.ascendispharma.jp. Revenue $10.3 Million. Industry Pharmaceuticals Healthcare . Recent News & Media. No recent news or media. Overview ; Who is Ascendis Pharma. Ascendis …See details»
Ascendis Pharma A/S Announces New Commercial Endocrinology …
May 23, 2022 Reflecting on his time at Ascendis, Mr. Høiland said, “It has been a privilege to establish the Ascendis endocrinology commercial organization and launch SKYTROFA in the …See details»
Ascendis Pharma A/S
Jan 7, 2024 • Expanding reach for SKYTROFA through Ascendis commercial organization building on therapeutic synergies • Full year 2024 SKYTROFA revenue expected to be €320 …See details»